Bromocriptine Shortage: What Providers and Prescribers Need to Know in 2026

Bromocriptine (Parlodel, Cycloset) presents unique supply chain challenges compared to most oral medications. Its ergot-alkaloid derivation, multi-indication profile, and the brand-only status of its Cycloset formulation mean that availability issues arise regularly in clinical practice — even when no formal FDA shortage is declared. This guide helps prescribers anticipate, manage, and communicate around bromocriptine availability challenges.

Current Availability Status (2026)

Generic bromocriptine mesylate (2.5 mg tablets and 5 mg capsules — the Parlodel formulation) is not currently listed on the FDA Drug Shortage Database. Multiple generic manufacturers supply the market, providing reasonable national availability. Localized stock-outs at individual pharmacies, however, remain common due to low formulary prioritization.

Cycloset (bromocriptine mesylate 0.8 mg quick-release) has no generic equivalent and is more consistently difficult to locate at retail pharmacies. Its niche indication — type 2 diabetes adjunct therapy — means fewer pharmacies stock it proactively. Specialty and mail-order pharmacies tend to be the most reliable dispensers.

Key Clinical Distinction: Parlodel vs. Cycloset Are Not Interchangeable

This point cannot be overstated in the clinical context. Parlodel and Cycloset contain the same active ingredient but differ fundamentally in:

Release formulation: Cycloset is a quick-release formulation; Parlodel is standard-release

Strength: Cycloset 0.8 mg vs. Parlodel 2.5–5 mg

Indication: Cycloset is FDA-approved only for type 2 diabetes; Parlodel is approved for hyperprolactinemia, Parkinson's disease, and acromegaly

Timing: Cycloset must be taken within 2 hours of waking; Parlodel timing varies by indication

Pharmacies cannot legally substitute one for the other, and clinicians should write prescriptions specifying the exact brand and dosage form to avoid confusion.

Therapeutic Alternatives by Indication

Hyperprolactinemia / Prolactinomas

Cabergoline (Dostinex) is the preferred dopamine agonist per current Endocrine Society and Pituitary Society guidelines. Multiple meta-analyses confirm superior efficacy in normalizing prolactin levels and restoring reproductive function, with better tolerability. The half-life of 65-70 hours allows once- or twice-weekly dosing. Generic cabergoline is available. The primary concern is dose-dependent cardiac valvulopathy, which is more significant at Parkinson's doses than prolactinoma doses.

Parkinson's Disease

Ergot dopamine agonists including bromocriptine are not recommended as first-line treatment for Parkinson's disease due to fibrotic risks. Non-ergot dopamine agonists — pramipexole (Mirapex) and ropinirole (Requip) — are standard of care. If a patient is currently managed on bromocriptine for Parkinson's and can no longer access it, transitioning to a non-ergot dopamine agonist with a supervised taper/titration is appropriate.

Acromegaly

Bromocriptine is rarely first-line for acromegaly. Somatostatin receptor ligands (octreotide, lanreotide, pasireotide) and GH receptor antagonists (pegvisomant) are preferred. If bromocriptine is being used as a cost-effective adjunct, discuss transition options with endocrinology.

Type 2 Diabetes (Cycloset)

Cycloset is an add-on agent and not first-line therapy. Its glycemic effect is modest (HbA1c reduction approximately 0.5-1.0%). If unavailable, replacing it with an evidence-based add-on agent — SGLT2 inhibitor, GLP-1 RA, DPP-4 inhibitor, or sulfonylurea — based on the patient's individual risk profile and cardiovascular/renal comorbidities is appropriate.

Communicating with Patients About Availability Issues

When patients report difficulty filling bromocriptine, providers can take these steps:

Advise early refills: Patients on ongoing therapy should refill 7-10 days before running out.

Specify formulation explicitly: Write "bromocriptine mesylate 2.5 mg tablet" or "Cycloset 0.8 mg tablet" to prevent pharmacy confusion.

Refer patients to medfinder: medfinder calls pharmacies near the patient to locate their exact medication — a practical tool to share with patients struggling to fill their prescription.

Consider 90-day fills via mail-order: Write a 90-day prescription for ongoing patients to encourage mail-order pharmacy use, which reduces supply disruptions.

For additional clinical tools and resources to help your patients navigate medication access challenges, visit medfinder for providers. You can also read our detailed provider guide on helping patients find bromocriptine in stock.